Literature DB >> 19758213

Sugar-free antibodies--the bacterial solution to autoimmunity?

Maria Allhorn1, Mattias Collin.   

Abstract

The enzyme EndoS from Streptococcus pyogenes is an immunomodulatory molecule hydrolyzing the conserved glycans in the effector part of immunoglobulin G (IgG). EndoS is remarkably specific for IgG, and hydrolysis has profound effects on IgG effector functions. EndoS pretreatment of IgG, or direct administration to animals with experimental antibody-mediated autoimmune diseases, inhibits development of disease or cures animals from established disease. The properties of EndoS make it a unique experimental tool and an attractive alternative to current therapies of conditions involving pathogenic antibodies. This review describes the discovery of EndoS, the effects of EndoS on IgG effector functions in vitro and in vivo, the biotechnological potential of EndoS, and the outcomes of EndoS treatment in animal models of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758213     DOI: 10.1111/j.1749-6632.2009.04739.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

1.  Therapeutic potential of deglycosylated antibodies.

Authors:  Max Crispin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-07       Impact factor: 11.205

2.  Antiphagocytic function of an IgG glycosyl hydrolase from Streptococcus equi subsp. equi and its use as a vaccine component.

Authors:  Margareta Flock; Lars Frykberg; Markus Sköld; Bengt Guss; Jan-Ingmar Flock
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

3.  GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins.

Authors:  Leander Meuris; Francis Santens; Greg Elson; Nele Festjens; Morgane Boone; Anaëlle Dos Santos; Simon Devos; François Rousseau; Evelyn Plets; Erica Houthuys; Pauline Malinge; Giovanni Magistrelli; Laura Cons; Laurence Chatel; Bart Devreese; Nico Callewaert
Journal:  Nat Biotechnol       Date:  2014-04-20       Impact factor: 54.908

4.  Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.

Authors:  Mohey Eldin El Shikh; Maciej Kmieciak; Masoud H Manjili; Andras K Szakal; Costantino Pitzalis; John G Tew
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

5.  Deficiency of activating Fcγ-receptors reduces hepatic clearance and deposition of IC and increases CIC levels in mercury-induced autoimmunity.

Authors:  Klara Martinsson; Thomas Skogh; Seyed Ali Mousavi; Trond Berg; Jan-Ingvar Jönsson; Per Hultman
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

6.  Study of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence.

Authors:  Jonathan Sjögren; Cheryl Y M Okumura; Mattias Collin; Victor Nizet; Andrew Hollands
Journal:  BMC Microbiol       Date:  2011-05-27       Impact factor: 3.605

7.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15

Review 8.  Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies.

Authors:  Ngoc Phuong Lan Le; Thomas A Bowden; Weston B Struwe; Max Crispin
Journal:  Biochim Biophys Acta       Date:  2016-04-20

Review 9.  Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.

Authors:  Yusuke Mimura; Toshihiko Katoh; Radka Saldova; Roisin O'Flaherty; Tomonori Izumi; Yuka Mimura-Kimura; Toshiaki Utsunomiya; Yoichi Mizukami; Kenji Yamamoto; Tsuneo Matsumoto; Pauline M Rudd
Journal:  Protein Cell       Date:  2017-06-08       Impact factor: 14.870

10.  Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencing.

Authors:  Anja Resemann; Wolfgang Jabs; Anja Wiechmann; Elsa Wagner; Olivier Colas; Waltraud Evers; Eckhard Belau; Lars Vorwerg; Catherine Evans; Alain Beck; Detlev Suckau
Journal:  MAbs       Date:  2016-01-13       Impact factor: 5.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.